Cost-effectiveness analysis for midostaurin versus standard of care in acute myeloid leukemia in the United Kingdom

Table 5 Health state utilities used in the model

Utility state	Utility values used in base case (literature)	Values used in scenario analysis (TTO)	Reference (literature values)	Data source
Induction treatment^a	0.648	0.162	Uyl-de Groot et al. 1998 [18]	Measured EQ-5D
Consolidation treatment^a	0.710	0.568	Batty et al. 2014 [19]	Calculated from published literature
Monotherapy treatment^a	0.810	0.889	Batty et al. 2014 [19]	Calculated from published literature
Complete remission	0.830	0.887	Leunis et al. 2014 [29]	Measured EQ-5D
Relapse	0.530	0.505	Pan et al. 2010 [30]	Mapped from QLQ-C30
SCT treatment^a	0.613	− 0.210	Source for algorithm—Crott et al. 2010 [27]; Source of QLQC30 data—Grulke et al. 2012 [28]	Mapped from QLQ-C30
SCT recovery	0.810	0.748	Source for algorithm—Crott et al. 2010 [27]; Source of QLQC30 data—Grulke et al. 2012 [28]	Mapped from QLQ-C30
Post-SCT recovery	0.826	0.715	Source for algorithm—Crott et al. 2010 [27]; Source of QLQC30 data—Grulke et al. 2012 [28]	Mapped from QLQ-C30

TTO time trade-off, STC stem cell transplantation, QLQC30 Quality of Life Questionnaire Core 30 (produced by the European Organization for Research and Treatment of Cancer)
^aIncludes treatment disutility

ISSN: 1478-7547